RASTELLI, Giulio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.854
AS - Asia 9.765
EU - Europa 9.101
SA - Sud America 1.531
Continente sconosciuto - Info sul continente non disponibili 340
AF - Africa 227
OC - Oceania 58
Totale 44.876
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.310
SG - Singapore 3.007
GB - Regno Unito 2.603
CN - Cina 2.576
IT - Italia 1.811
BR - Brasile 1.184
HK - Hong Kong 1.158
VN - Vietnam 1.099
SE - Svezia 975
DE - Germania 936
FI - Finlandia 504
BD - Bangladesh 454
RU - Federazione Russa 424
UA - Ucraina 387
PL - Polonia 365
FR - Francia 294
CA - Canada 267
TR - Turchia 265
KR - Corea 259
IN - India 231
ID - Indonesia 176
BG - Bulgaria 164
NL - Olanda 149
AR - Argentina 121
MX - Messico 105
ES - Italia 98
JP - Giappone 79
IQ - Iraq 71
BE - Belgio 67
IE - Irlanda 63
LT - Lituania 55
ZA - Sudafrica 55
AU - Australia 54
EC - Ecuador 52
PK - Pakistan 52
CO - Colombia 49
AE - Emirati Arabi Uniti 43
AT - Austria 39
VE - Venezuela 38
CL - Cile 34
UZ - Uzbekistan 34
CR - Costa Rica 33
MA - Marocco 33
EG - Egitto 28
SA - Arabia Saudita 27
GT - Guatemala 26
IR - Iran 26
PH - Filippine 25
HN - Honduras 22
RO - Romania 22
CH - Svizzera 21
KE - Kenya 21
JO - Giordania 20
MY - Malesia 20
TN - Tunisia 17
UY - Uruguay 17
AZ - Azerbaigian 16
PR - Porto Rico 16
DO - Repubblica Dominicana 15
JM - Giamaica 15
PY - Paraguay 15
TT - Trinidad e Tobago 15
TH - Thailandia 14
DZ - Algeria 13
KZ - Kazakistan 13
NP - Nepal 13
IL - Israele 12
PT - Portogallo 12
HU - Ungheria 11
AL - Albania 10
CI - Costa d'Avorio 10
RS - Serbia 10
BO - Bolivia 9
BY - Bielorussia 9
HR - Croazia 9
NG - Nigeria 9
NO - Norvegia 9
PE - Perù 9
SK - Slovacchia (Repubblica Slovacca) 9
TW - Taiwan 9
ET - Etiopia 8
GR - Grecia 8
KH - Cambogia 8
LK - Sri Lanka 8
OM - Oman 8
SN - Senegal 8
CZ - Repubblica Ceca 7
EU - Europa 7
SC - Seychelles 7
AO - Angola 6
EE - Estonia 6
LB - Libano 6
NI - Nicaragua 6
PA - Panama 6
BB - Barbados 5
BH - Bahrain 5
CY - Cipro 5
DK - Danimarca 5
QA - Qatar 5
SI - Slovenia 4
Totale 44.475
Salva come PNG Salva come JPEG
Città #
Ashburn 2.887
Fairfield 2.304
Santa Clara 1.963
Southend 1.675
Singapore 1.608
Woodbridge 1.292
Hong Kong 1.127
Houston 1.030
Chandler 996
Seattle 924
San Jose 901
Hefei 865
Council Bluffs 821
Cambridge 804
Wilmington 741
Jacksonville 738
Ann Arbor 602
Nyköping 567
Dearborn 558
London 486
Beijing 464
Helsinki 359
Ho Chi Minh City 350
Warsaw 349
Los Angeles 321
Hanoi 265
Modena 255
Seoul 238
The Dalles 234
Milan 229
New York 225
Chicago 224
Dallas 202
San Diego 192
Princeton 165
Sofia 155
Munich 143
Eugene 132
Lauterbourg 121
Berlin 118
Izmir 115
São Paulo 115
Jakarta 114
Buffalo 106
Des Moines 103
Bologna 101
Shanghai 94
Salt Lake City 86
Frankfurt am Main 85
Moscow 78
Boardman 73
Columbus 73
Orem 73
Rome 69
Phoenix 64
Toronto 64
Tokyo 63
Brussels 58
Washington 58
Dublin 54
Atlanta 48
Mexico City 47
Porto Alegre 44
Tampa 43
Da Nang 42
Amsterdam 41
Reggio Emilia 41
Chennai 40
Guangzhou 40
Haiphong 40
Brooklyn 39
Redwood City 39
Bremen 38
Denver 38
Elk Grove Village 38
Kent 36
Naples 35
Falls Church 34
Rio de Janeiro 33
Groningen 32
Miano 30
Montreal 29
Parma 29
Tashkent 29
Norwalk 28
San Francisco 28
San José 28
Baghdad 27
North Charleston 27
Nuremberg 27
Biên Hòa 26
Paris 26
Johannesburg 25
Boston 24
Belo Horizonte 23
Philadelphia 23
Saint Augustine 23
Brasília 22
Canberra 22
Guatemala City 22
Totale 30.582
Salva come PNG Salva come JPEG
Nome #
The 1,2,3-triazole ring as a bioisostere in medicinal chemistry 1.368
Polypharmacology: challenges and opportunities in drug discovery 538
1-Benzopyran-4-one antioxidants as aldose reductase inhibitors 492
7-Hydroxy-2-substituted-4-H-1-benzopyran-4-one derivatives as aldose reductase inhibitors: a SAR study 458
Structural models and binding site prediction of the C-terminal domain of human Hsp90: a new target for anticancer drugs 445
Analytical and Simulation-Based Models for Drug Release and Gel-Degradation in a Tetra-PEG Hydrogel Drug-Delivery System 407
BEAR, a Molecular Docking Refinement and Rescoring Method 398
An unexpected reversal in the pharmacological stereoselectivity of benzothiadiazine AMPA positive allosteric modulators 398
Synthesis and biological activities of novel 17-aminogeldanamycin derivatives 396
A rational approach to the design of flavones as xanthine oxidase inhibitors 393
Application of a post-docking procedure based on MM-PBSA and MM-GBSA on single and multiple protein conformations 393
Molecular docking: Shifting paradigms in drug discovery 388
Aldose reductase does catalyse the reduction of glyceraldehyde through a stoichiometric oxidation of NADPH. 381
Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases 361
Fruits of ribes, rubus, vaccinium and prunus genus. Metal contents and genome 357
Role of bifidobacteria in the hydrolysis of chlorogenic acid 356
Advances and applications of binding affinity prediction methods in drug discovery 354
A model of the interaction of substrates and inhibitors with xanthine oxidase 353
Structure-Based Design of Potent Aromatase Inhibitors by High-Throughput Docking 352
New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications 350
A computational workflow for the design of irreversible inhibitors of protein kinases 350
Fast and accurate predictions of relative binding free energies using MM-PBSA and MM-GBSA 348
1H-NMR conformational studies of some phtalein derivatives acting as thymidylate synthase inhibitors 347
Antifungal Activity and DNA Topoisomerase Inhibition of Hydrolysable Tannins from Punica granatum L. 347
Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors 344
Conformational analysis of phthalein derivatives acting as thymidylate synthase inhibitors by means of 1H NMR and quantum chemical calculations 344
Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase 343
Activity prediction and structural insights of Extracellular Signal-Regulated Kinase 2 inhibitors with molecular dynamics simulations 339
Molecular dynamics simulations and classical multidimensional scaling unveil new metastable states in the conformational landscape of CDK2 336
On the integration of in silico drug design methods for drug repurposing 336
Binding of 1-benzopyran-4-one derivatives to aldose reductase: A free energy perturbation study 333
Valutazione tossicologica di due nuovi inibitori della DHFR del P. falciparum e del P. vivax 332
Grid-enabled high throughput virtual screening 332
BEAR, a novel virtual screening methodology for drug discovery 331
WISDOM-II: Screening against multiple targets implicated in malaria using computational grid infrastructures 326
Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs) 323
Selection of protein conformations for structure-based polypharmacology studies 322
Identification of small-molecule EGFR allosteric inhibitors by high-Throughput docking 320
Theoretical analysis of the addition of hydroxylamine to uracil and 5-fluorouracil as a model for the Thymidylate synthase reaction 319
Binding estimation after refinement, a new automated procedure for the refinement and rescoring of docked ligands in virtual screening 315
Virtual screening on large scale grids 313
Structure-based design of an inhibitor modeled at the substrate active site of aldose reductase 310
Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank 309
A series of diarylsubstituted oximes as potential substrates for new aldose reductase inhibitors 308
Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: Discovery and computational modeling of a new series of ligands with nanomolar affinity 307
Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors 306
Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease 302
Mutational analysis of Plasmodium falciparum dihydrofolate reductase: the role of aspartate 54 and phenylalanine 223 on catalytic activity and antifolate binding 299
Heat shock protein 90 and serine/threonine kinase B-Raf inhibitors have overlapping chemical space 299
Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches 297
Fruit of ribes, rubus, vaccinium and prunus genus, metals content and genome 295
Structural bases for the inhibition of aldose reductase by phenolic compounds 293
Enrichment Factor Analyses on G-Protein Coupled Receptors with Known Crystal Structure 290
αC helix displacement as a general approach for allosteric modulation of protein kinases 290
Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2 287
Exploration and Comparison of the Geometrical and Physicochemical Properties of an αc Allosteric Pocket in the Structural Kinome 286
In vitro effects of Plasmodium falciparum dihydrofolate reductase inhibitors on normal and cancer cell proliferation 285
Nitrophenyl derivatives as Aldose Reductase inhibitors 285
Computational polypharmacology analysis of the heat shock protein 90 interactome 285
Identification of 4-aryl-1H-pyrrole[2,3-b]pyridine derivatives for the development of new B-Raf inhibitors 285
ANTHOCYANIDINES AS INHIBITORS OF XANTHINE-OXIDASE 282
Preparation of thieno[3,2-h]cinnolinones as matrix metalloproteinase inhibitors 282
Exploring the binding site of C-terminal Hsp90 inhibitors 282
Structure–Activity Relationships of Hexahydrocyclopenta[c]quinoline Derivatives as Allosteric Inhibitors of CDK2 and EGFR 282
Pharmacological approaches to the treatment of diabetic complications 281
Structure of Plasmodium vivax dihydrofolate reductase determined by homology modeling and molecular dynamics refinement 280
Histone deacetylases: Structural determinants of inhibitor selectivity 280
Quantitative measurement of proton dissociation and tautomeric constants of apigeninidin 280
Prediction of activity and selectivity profiles of human Carbonic Anhydrase inhibitors using machine learning classification models 280
Investigating the Selectivity of Allosteric Inhibitors for Mutant T790M EGFR over Wild Type Using Molecular Dynamics and Binding Free Energy Calculations 278
Evaluation of Amides, Carbamates, Sulfonamides, and Ureas of 4-Prop-2-ynylidenecycloalkylamine as Potent, Selective, and Bioavailable Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 276
Discovery of new inhibitors of aldose reductase from molecular docking and database screening 275
Composition, Superoxide Radicals Scavenging and Antilipoperoxidant Activity of some Edible Fruits 273
Physico-chemical properties of anthocyanidins. Part 1. Theoretical evaluation of the stability of the neutral and anionic tautomeric forms 272
Design and discovery of plasmepsin inhibitors using an automated workflow on large scale grids 272
Promiscuity of inhibitors of human protein kinases at varying data confidence levels and test frequencies 272
Conformational analysis, molecular modeling and quantitative structure-activity relationships studies of 2,4-diamino-6,7-dimethoxy-2-substituted quinazoline α1-adrenergic antagonists 271
Structure-based design of 7-carbamate analogs of geldanamycin 270
Oxidative modification of aldose reductase induced by copper ion. Factors and conditions affecting the process 269
Molecular modeling and crystal structure of ERK2-Hypothemycin complexes 268
Novel and less explored chemotypes of natural origin for the inhibition of Hsp90 268
Model chemical studies of thymidylate synthase. Nucleophilic addition of hydroxylamine to uracil and 5-fluorouracil 267
Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer 266
Relationship between quantum-chemical descriptors of proton dissociation and experimental acidity contants of variously hydroxylated coumarins. Identification of the biologically active species for xanthine oxidase inhibition 264
Design of dual inhibitors of histone deacetylase 6 and heat shock protein 90 264
Activité Antilipoperoxydante d'Extraits Polyphenoliques de Ribes Nigrum L. 262
Targeting the Hsp90 interactome using in silico polypharmacology approaches 262
Assessing protein kinase selectivity with molecular dynamics and MM-PBSA binding free energy calculations. 261
Ortho-halogen naphthaleins as specific inhibitors of Lactobacillus casei thymidylate synthase. Conformational properties and biological activity 260
Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with Plasmodium falciparum dihydrofolate reductase: Structural basis of antifolate resistance 259
Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach 258
Solvent effects on the tautomerism of apigeninidin 254
Insight into the specificity of Thymidylate synthase from molecular dynamics and free-energy perturbation calculations 252
QSAR analysis in 2,4-diamino-6,7-dimethoxy quinoline derivatives - α1-adrenoceptor antagonists - using the partial least squares (PLS) method and theoretical molecular descriptors 250
Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors 250
Computational polypharmacology comes of age 250
Improving enrichment and hit rate in virtual screening 248
LigAdvisor: A versatile and user-friendly web-platform for drug design 248
Theoretical and experimental study of flavones as inhibitors of xanthine oxidase 247
Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90 245
Totale 32.216
Salva come PNG Salva come JPEG
Categoria #
all - tutte 168.406
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 168.406
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.158 0 0 0 164 72 146 209 167 296 254 527 323
2022/20232.952 396 372 215 229 317 435 79 267 399 48 138 57
2023/20241.863 62 121 126 154 427 144 159 314 36 41 79 200
2024/20257.333 254 66 120 499 1.288 953 367 627 683 800 775 901
2025/202613.033 806 665 1.210 1.486 1.525 1.187 1.385 644 1.268 1.291 928 638
2026/20273.692 458 823 947 1.464 0 0 0 0 0 0 0 0
Totale 44.876